What is it about?
The article discusses how routine pharmaceutical quality control and environmental testing primarily focus on detecting bacteria and fungi, completely overlooking a distinct domain of microorganisms known as Archaea. Archaea are an ancient form of life that can be found in a wide variety of habitats, ranging from extreme environmental conditions to oceans, soil, and even the human skin and colon. Because most Archaea members require unique conditions and cannot be grown using standard laboratory culture media, they remain largely undetected by conventional testing methods used in the pharmaceutical industry.
Featured Image
Photo by Meg von Haartman on Unsplash
Why is it important?
Strict microbiological monitoring of manufacturing environments, pharmaceutical water, and compressed gases is a critical prerequisite for releasing safe medical products into the market. Archaea possess unique enzyme systems that allow them to survive harsh chemical and physical conditions that would normally kill regular bacteria. These microbes have the ability to form biofilms, which could potentially damage pharmaceutical water stations and spoil products with a high water content, such as liquid oral medications and topical creams. As the number of patients with defective immune systems or those taking immunosuppressive medications continues to grow, underestimating these undetectable microbes poses a potential risk for unforeseen outbreaks.
Perspectives
Testing Limitations: The author emphasizes that traditional microbiological culture media are inherently flawed for this task, as they fail to detect microbes that enter a "viable-but-not-culturable" (VBNC) state. To effectively detect Archaea, the industry would need to rely on newer, albeit more expensive, molecular technologies. Regulatory Gaps: The Food and Drug Administration (FDA) continuously updates its list of objectionable microbes, many of which are not yet covered by official guidelines like the pharmacopeia. The author argues that pharmaceutical firms must use intelligent risk assessment approaches to justify testing for specific microbial groups. A Call for Vigilance: While there is currently no strong proof linking Archaea to human pathogenesis, the author warns against the assumption that they are entirely harmless. The article urges that the pharmaceutical sector must conduct extensive scientific studies to properly evaluate the risks these microbes pose before an outbreak occurs.
Independent Researcher & Consultant Mostafa Essam Eissa
Read the Original
This page is a summary of: Archaea: Underestimated Domain in Pharmaceutical Quality Control, Kathmandu University Journal of Science Engineering and Technology, October 2018, Kathmandu University,
DOI: 10.3126/kuset.v13i2.21288.
You can read the full text:
Contributors
The following have contributed to this page
